Sanofi-Aventis’s chief executive, Chris Viehbacher, took his case for a takeover directly to Genzyme’s investors in meetings in New York on Tuesday, Bloomberg News reported, citing two people who attended. Mr. Viehbacher told investors he isn’t getting feedback from Genzyme management on his Aug. 28 offer of $69 a share, or about $18.5 billion, said [...]
Henri Termeer, a biotech industry pioneer and chief executive officer at Genzyme, is on the verge of losing control of the company he transformed from a start-up in 1983 into a cutting-edge drugmaker with $4.5 billion in annual sales, Bloomberg News reported. Pressured by an unsolicited $18.5 billion buyout offer from Paris-based Sanofi-Aventis, activist investors [...]
From Reuters Breakingviews: “Let me in, and I might go higher.” That, in a nutshell, is the message Chris Viehbacher, the chief executive of Sanofi-Aventis, is sending the management of the biotech company Genzyme in making public his $18.5 billion offer to buy it. The all-cash structure is intended to show that Sanofi-Aventis, the French [...]
The chief executive of Genzyme, Henri A. Termeer, on Tuesday appeared to soften his tone about a possible sale, a day after his company rejected a $69-a-share offer from Sanofi-Aventis. In an interview with The Boston Globe, Mr. Termeer acknoweldged that Genzyme was now in play even as he reiterated that Sanofi’s price undervalued the [...]
The chief executive of Genzyme, Henri A. Termeer, on Tuesday appeared to soften his tone about a possible sale, a day after his company rejected a $69-a-share offer from Sanofi-Aventis. In an interview with The Boston Globe, Mr. Termeer acknoweldged that Genzyme was now in play even as he reiterated that Sanofi’s price undervalued the [...]
The chief executive of Genzyme, Henri A. Termeer, on Tuesday appeared to soften his tone about a possible sale, a day after his company rejected a $69-a-share offer from Sanofi-Aventis. In an interview with The Boston Globe, Mr. Termeer acknoweldged that Genzyme was now in play even as he reiterated that Sanofi’s price undervalued the [...]
Twitter
Facebook